Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Researcher index
Authors in the psilocybin and psilocin literature
Search researcher names, inspect publication history, find recurring topics, and create author watch alerts without collecting unverified contact lists.
Publication history
Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. AdultsAmerican Journal of Preventive Medicine · 2026-10-01Balancing safety and access in Oregon’s psilocybin servicesInternational Journal of Drug Policy · 2026-09-01An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in LifeClinicalTrials.gov · 2026-08-17Psilocybin Administration With 5-HT1a BlockadeClinicalTrials.gov · 2026-08-14A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in VeteransClinicalTrials.gov · 2026-08-14Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study)ClinicalTrials.gov · 2026-08-13Real-world use, safety, and mental health efficacy of regulated psilocybin services in Oregon and ColoradomedRxiv · 2026-08-12Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use DisorderClinicalTrials.gov · 2026-08-12Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and SuicidalityClinicalTrials.gov · 2026-08-12A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety DisorderClinicalTrials.gov · 2026-08-12An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study)ClinicalTrials.gov · 2026-08-10A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older AdultsClinicalTrials.gov · 2026-08-10Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot StudyClinicalTrials.gov · 2026-08-10Advanced research eyes potential of psychedelics for complex casesMental Health Weekly · 2026-08-07Open Label Psilocybin Brain Stimulation and Imaging Pilot StudyClinicalTrials.gov · 2026-08-07Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand MechanismClinicalTrials.gov · 2026-08-06An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic TherapyClinicalTrials.gov · 2026-08-06Psilocybin as a Treatment for Chronic Pain in SmokersClinicalTrials.gov · 2026-08-03Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility StudyClinicalTrials.gov · 2026-08-03Evaluating psilocybin for the management of depression: a literature reviewBritish Journal of Mental Health Nursing · 2026-08-02From trial to clinic: psilocybin's efficacy in routine treatment-resistant depression.The Lancet regional health. Europe · 2026-08-01Childhood trauma and psychological outcomes following psychedelic use: a scoping reviewnpj Mental Health Research · 2026-07-30Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)ClinicalTrials.gov · 2026-07-30Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical TrialClinicalTrials.gov · 2026-07-30Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical TrialClinicalTrials.gov · 2026-07-30Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of PsilocybinClinicalTrials.gov · 2026-07-29Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin.ClinicalTrials.gov · 2026-07-28Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical TrialClinicalTrials.gov · 2026-07-28Effects of Psilocybin on Electrophysiology and the Dynamic Content of ThoughtClinicalTrials.gov · 2026-07-23A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)ClinicalTrials.gov · 2026-07-23PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin PretreatmentClinicalTrials.gov · 2026-07-21Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]ClinicalTrials.gov · 2026-07-21Learnings from a hybrid communities of practice group therapy model to support psilocybin-assisted therapy for patients with a terminal diagnosisFrontiers in Public Health · 2026-07-20A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of PsilocybinClinicalTrials.gov · 2026-07-17Psychedelic Therapies in the Management of Post-Traumatic Stress DisorderJournal of Education Health and Sport · 2026-07-16Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy OutcomesClinicalTrials.gov · 2026-07-16Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled TrialClinicalTrials.gov · 2026-07-14Mechanistic Studies of Psilocybin in Headache DisordersClinicalTrials.gov · 2026-07-13PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-10The Effects of Psilocybin on Social ConnectednessClinicalTrials.gov · 2026-07-09Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)ClinicalTrials.gov · 2026-07-09Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic EffectsClinicalTrials.gov · 2026-07-09Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone FormulationClinicalTrials.gov · 2026-07-07Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health SymptomsJournal of Drug Issues · 2026-07-01Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label TrialClinicalTrials.gov · 2026-06-26Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy SubjectsClinicalTrials.gov · 2026-06-25Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label TrialClinicalTrials.gov · 2026-06-23Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label TrialClinicalTrials.gov · 2026-06-22Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New MexicoFrontiers in Public Health · 2026-06-17The Acute Effects of Psilocybin on Cognition, Memory, and Brain FunctionClinicalTrials.gov · 2026-06-15A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's DiseaseClinicalTrials.gov · 2026-06-08Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-samplingClinicalTrials.gov · 2026-06-05Developing Methods for Observing Awe Narration in Psilocybin-Assisted TherapyHealthcare · 2026-06-052 x 2 Factorial, Double-blind, Randomized Trial of 'Set and Setting': a Translational Study in Healthy VolunteersClinicalTrials.gov · 2026-06-04Bringing Psilocybin-Assisted Therapy to Palliative Oncology: Early Lessons from Real-World ImplementationHealthcare · 2026-06-03Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual AnhedoniaClinicalTrials.gov · 2026-05-27Psilocybin-Assisted Therapy for Adolescent Anorexia Nervosa: Clinical Considerations and Emerging Models of CareCurrent Psychiatry Reports · 2026-05-14Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based SampleClinicalTrials.gov · 2026-05-12The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.ClinicalTrials.gov · 2026-05-08Does Psilocybin Require Psychedelic Effects to Treat Depression? A 4-Week, Double-Blind, Proof-of-Concept Randomized Controlled TrialClinicalTrials.gov · 2026-05-07Pilot Results for Psilocybin-Assisted Psychotherapy for Cocaine Use Disorder-A Critical AppraisalJAMA Network Open · 2026-05-07Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled TrialClinicalTrials.gov · 2026-05-01Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamineGeneral Hospital Psychiatry · 2026-05-01Psilocybin-Enhanced Psychotherapy for Methamphetamine Use DisorderClinicalTrials.gov · 2026-04-22Prevalence and Correlates of Past-Year Psilocybin Use in the United StatesAmerican Journal of Psychiatry · 2026-04-22Psychedelics: Historical Context, Emerging Science, and Future Clinical FrontiersJournal of Mental Health Disorders · 2026-04-18Psilocybin Trends in States That Decriminalized UseJAMA · 2026-04-14A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experienceFrontiers in Public Health · 2026-04-14Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy ParticipantsClinicalTrials.gov · 2026-04-02Clinical Characteristics of Emergency Visits Related to Recreational Psychedelic Use.Community mental health journal · 2026-04-01Classic psychedelics in obsessive-compulsive disorder: a circuit-based frameworkNature Mental Health · 2026-03-31Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in DepressionClinicalTrials.gov · 2026-03-30Psilocybin retail stores in Canada: Changes in availability, commercialization, and geographic distributionCanadian Journal of Public Health · 2026-03-19The renaissance of research on psychedelics in child and adolescent psychopharmacology.Child and adolescent psychiatry and mental health · 2026-03-13Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept StudyClinicalTrials.gov · 2026-03-11Psilocybin microdosing in the United States: Insights from a nationally representative surveyAddiction · 2026-03-08Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome.ClinicalTrials.gov · 2026-03-05Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept TrialClinicalTrials.gov · 2026-03-04Public attitudes diverge sharply on legal use of psychedelicsMental Health Weekly · 2026-03-02Cost-Effectiveness of Psilocybin-Assisted Therapy Versus Standard of Care for Patients With Treatment-Resistant DepressionValue in Health Regional Issues · 2026-03-01Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive ImpairmentClinicalTrials.gov · 2026-02-25The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers.ClinicalTrials.gov · 2026-02-25Investigation of Psychedelic Effects in Psychoactive SubstancesClinicalTrials.gov · 2026-02-23Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis.Qualitative health research · 2026-02-17A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy VolunteersClinicalTrials.gov · 2026-02-13Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical TrialClinicalTrials.gov · 2026-02-12Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy VolunteersClinicalTrials.gov · 2026-02-05RAND: Microdosing surges as millions turned to psychedelics in 2025Mental Health Weekly · 2026-01-23A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone TreatmentClinicalTrials.gov · 2026-01-23Healthcare Providers' Perspectives on Psychedelic-Assisted Therapies Across Clinical Contexts: "I Can Offer Medical Assistance in Dying, but I Can't Prescribe Psychedelics".Global advances in integrative medicine and health · 2026-01-01Rural-Urban Disparities in Access to Interventional Psychiatry Treatments among VA Patients.Rural mental health · 2026-01-01The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal IdeationClinicalTrials.gov · 2025-12-24Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who StutterClinicalTrials.gov · 2025-12-22A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced CancerClinicalTrials.gov · 2025-12-04Psychedelic Assisted Psychotherapy (PAP): the Geneva University Hospital modelEmerging Trends in Drugs Addictions and Health · 2025-12-01Psilocybin and Neuroplasticity: Mechanisms, Therapeutic Potential, and Future DirectionsEmerging Trends in Drugs Addictions and Health · 2025-12-01Meaning and Purpose Therapy Modified for Psilocybin (P-MaP): A Treatment Model for Palliative Care PatientsJournal of Health Service Psychology · 2025-12-01Psilocybin vs Ketamine for Alcohol Use DisorderClinicalTrials.gov · 2025-11-28Digital Intervention for Psychedelic Preparation (DIPP): A Randomised Controlled Feasibility Trial Comparing Meditation and Music-Based Programs in Healthy Volunteers.ClinicalTrials.gov · 2025-11-26Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive DisorderClinicalTrials.gov · 2025-11-26Does Serotonin System Stimulation Increase Pro-social Behavior? - A Comparative Pharmacological Neuroscientific Study in Healthy HumansClinicalTrials.gov · 2025-11-19A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant DepressionClinicalTrials.gov · 2025-11-19Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.ClinicalTrials.gov · 2025-11-19Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive DisorderClinicalTrials.gov · 2025-11-05Ketamine and psilocybin for athletes: A therapeutic breakthrough or a slippery slope?Performance Enhancement & Health · 2025-11-01A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From MethamphetamineClinicalTrials.gov · 2025-10-07S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19Supporting Meaningful Choices: A Decision Aid for Individuals Facing Existential Distress and Considering Psilocybin-Assisted Therapy.Healthcare (Basel, Switzerland) · 2025-09-12The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC)ClinicalTrials.gov · 2025-07-23A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy ParticipantsClinicalTrials.gov · 2025-06-12Comparison of the Effects of PEX20 (Oral Psilocin), PEX30 (Sublingual Psilocin), and PEX10 (Oral Psilocybin) in Healthy AdultsClinicalTrials.gov · 2025-06-10Minorities' Diminished Psychedelic Returns: Income and Educations Impact on Whites, Blacks, Hispanics, and Asians.Journal of racial and ethnic health disparities · 2025-06-01Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)ClinicalTrials.gov · 2025-05-28Consciousness and Psilocybin Effects on Well-Being (The CoPE Study): Pilot PhaseClinicalTrials.gov · 2025-05-16The Relationships Between Healthcare Access, Gender, and Psychedelics and Their Effects on Distress.Healthcare (Basel, Switzerland) · 2025-05-16Polysubstance Use Profiles Among the General Adult Population, United States, 2022.American journal of public health · 2025-05-01Patterns of Internalizing Problems, Substance Use and Cognitive Flexibility Before and After Naturalistic Psilocybin Use: A Repeated Measures Latent Profile AnalysisInternational Journal of Mental Health and Addiction · 2025-04-24Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects: A Placebo-controlled Cross-over Study (DMT BDR-Study).ClinicalTrials.gov · 2025-04-11Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAINClinicalTrials.gov · 2025-03-30Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in a Randomized, Placebo-controlled, Cross-over Trial in Healthy Participants (LPD-Study)ClinicalTrials.gov · 2025-03-27PSYCHEDELIC PHARMACOLOGY IN PSYCHIATRY: THE MECHANISMS AND THERAPEUTIC POTENTIAL OF PSILOCYBIN, MDMA, AND LSD IN MENTAL HEALTH DISORDERSJournal of medical & health sciences review. · 2025-03-11Risks of using psilocybin in treatment of treatment-resistant depressionJournal of Education Health and Sport · 2025-03-06Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy SubjectsClinicalTrials.gov · 2025-03-05BROAD SPECTRUM OF THERAPEUTIC PROPERTIES OF PSILOCYBIN: A LITERATURE REVIEWHealth Problems of Civilization · 2025-02-20A qualitative analysis of the psychedelic mushroom come-up and come-down.Npj mental health research · 2025-02-07The Acceptability of Psychedelic-Assisted Therapy Amongst Mental Health Consumers: Utilising the Theory of Planned Behaviour.International journal of mental health nursing · 2025-02-01A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major DepressionClinicalTrials.gov · 2025-01-20Study finds encouraging results in psilocybin treatment for TRD patientsMental Health Weekly · 2025-01-10PSYCHEDELICS IN THE TREATMENT OF MENTAL DISORDERSHealth and Society · 2025-01-08Moral Considerations and the Experience of Ego Dissolution: Insights from PsilocybinAsian Journal of Ethics in Health and Medicine · 2025-01-01Knowledge, perceptions, and use of psychedelics for mental health among autistic adults: An online survey.PLOS mental health · 2025-01-01Self-administered complementary and alternative methods of treating mental disorders among students in Wrocław: a cross-sectional study.Frontiers in public health · 2025-01-01Psychedelic-Assisted Therapy: The Emerging Role of the Psychiatric-Mental Health NurseSaudi Journal of Medicine and Public Health · 2024-12-31Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept StudyClinicalTrials.gov · 2024-12-04Differential in Vitro Activation Profiles for Psychedelic versus Non-psychedelic Ergolines at the 5-HT2A ReceptorEmerging Trends in Drugs Addictions and Health · 2024-12-01Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates.ClinicalTrials.gov · 2024-11-20PAPR: Psilocybin-assisted Psychotherapy + Mindfulness-Based Stress Reduction (MBSR) for Front-line Healthcare Provider COVID-19 Related BurnoutClinicalTrials.gov · 2024-11-12Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer.Nature. Mental health · 2024-11-01A Registered Clinical Trial of PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy StudyClinicalTrials.gov · 2024-10-30Psilocybin-assisted psychotherapy as an ‘anti-distressant’ with multidimensional propertiesNature Mental Health · 2024-10-14A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy ParticipantsClinicalTrials.gov · 2024-10-09Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome.Npj mental health research · 2024-10-06Use of Psilocybin in the Treatment of Mental Disorders: Systematic Review of Clinal TrialsJournal of Complementary Medicine & Alternative Healthcare · 2024-09-16A 24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)ClinicalTrials.gov · 2024-08-15An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)ClinicalTrials.gov · 2024-08-09Different hierarchical reconfigurations in the brain by psilocybin and escitalopram for depressionNature Mental Health · 2024-08-05Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in ReligionClinicalTrials.gov · 2024-06-18Psilocybin as a new way for depression treatmentJournal of Education Health and Sport · 2024-05-15Psilocybin Exposures Reported to U.S. Poison Centers: National Trends Over a Decade.The Journal of adolescent health: official publication of the Society for Adolescent Medicine · 2024-05-01Acute Dose-dependent Effects of DMT in Healthy Subjects: A Placebo-controlled Cross-over StudyClinicalTrials.gov · 2024-04-25Psychedelic therapists, pharma collaborate on clinical trialMental Health Weekly · 2024-04-13Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive DisorderInternational Journal of Mental Health and Addiction · 2024-03-07Post-traumatic stress symptoms, post-traumatic stress disorder, and post-traumatic growth among cancer survivors: a systematic scoping review of interventions.Health psychology review · 2024-03-01The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects.Npj mental health research · 2024-02-20Repeat Dosing of Psilocybin in Headache DisordersClinicalTrials.gov · 2024-02-09Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy SubjectsClinicalTrials.gov · 2024-01-24Cannabis and Psilocybin: Insurance Reimbursement, Legalization, and ReschedulingHealth Law Outlook · 2024-01-01Psilocybin - new remedy for patients with psychiatric disorders? Critical analysis of the current state of knowledgeJournal of Education Health and Sport · 2023-12-30Safety and Efficacy of Psilocybin for the Treatment of Headache DisordersClinicalTrials.gov · 2023-12-15A history and future of psychedelics: The case of the Canadian military.Journal of military, veteran and family health · 2023-12-01Studying classic psychedelics for the management of headache disorders: Considerations for Veterans.Journal of military, veteran and family health · 2023-12-01Psilocybin-assisted psychotherapy for treatment-resistant depression: Which psychotherapy?International journal of mental health nursing · 2023-12-01Managing expectations with psychedelic microdosingnpj Mental Health Research · 2023-11-08Assessing Metro Vancouver Residents’ Knowledge and Opinions of PsilocybinBCIT Environmental Public Health Journal · 2023-10-12Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study IIClinicalTrials.gov · 2023-10-12Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study IClinicalTrials.gov · 2023-10-12Effects and Therapeutic Potential of Psilocybin in Alcohol DependenceClinicalTrials.gov · 2023-09-26Mindfulness and Psychedelics: A Combined Neurophenomenological and Pharmacological Approach to the Characterization of Mindfulness States in Experienced MeditatorsClinicalTrials.gov · 2023-09-21use of psilocybin in the treatment of psychiatric disorders - reviewJournal of Education Health and Sport · 2023-08-15Psilocybin's Emerging Role in Combating Depressive DisorderJournal of Education Health and Sport · 2023-08-08Experiences of psilocybin treatment for clinical conditions: A qualitative meta-synthesis.International journal of mental health nursing · 2023-08-01Outcomes of usage of psychedelics by people reporting an eating disorder in clinical and non-clinical settings: a scoping reviewAdvances in Mental Health · 2023-07-13FDA issues first draft guidance on psychedelic researchMental Health Weekly · 2023-06-30Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress DisorderClinicalTrials.gov · 2023-06-29Psychedelics, Meaningfulness, and the "Proper Scope" of Medicine: Continuing the Conversation.Cambridge quarterly of healthcare ethics: CQ: the international journal of healthcare ethics committees · 2023-06-27Psilocybin therapy: A novel approach to treating depressionInternational Journal of Surgery Global Health · 2023-06-02Recall of Experience and Conscious Awareness in Psilocybin Treatment of Depression (The RECAP Study): Pilot Phase in Healthy Adult VolunteersClinicalTrials.gov · 2023-05-19A Phase 1 Study Comparing the Pharmacokinetics and Safety of Intravenous and Oral PsilocybinClinicalTrials.gov · 2023-05-15The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant DepressionClinicalTrials.gov · 2023-04-24Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of ConsciousnessClinicalTrials.gov · 2023-03-29Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding StudyClinicalTrials.gov · 2023-03-20Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist's Training?Cambridge quarterly of healthcare ethics: CQ: the international journal of healthcare ethics committees · 2023-03-02Psilocybin therapy for depression. A good trip?Journal of mental health (Abingdon, England) · 2023-02-01Medications for the Treatment of Alcohol Dependence-Current State of Knowledge and Future Perspectives from a Public Health Perspective.International journal of environmental research and public health · 2023-01-19A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol DependenceClinicalTrials.gov · 2022-11-08Experts assess role of therapists in psychedelic-assisted therapyMental Health Weekly · 2022-11-05The psychedelic renaissance: can psilocybin possibly combat depression?International Journal of Surgery Global Health · 2022-11-01The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.ClinicalTrials.gov · 2022-10-25Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP 001 And COMP 003 Trials (P-TRD LTFU)ClinicalTrials.gov · 2022-09-22Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a WorkshopNational Academies Press (US), Washington (DC) · 2022-09-01Use of psychedelics in the Czech Republic: results of recent population surveys.Central European journal of public health · 2022-09-01MSR20 Challenges in the Development of Economic Evaluations for Psychedelics in Treatment of DepressionValue in Health · 2022-06-24Applying Lessons From Cannabis to the Psychedelic HighwayJAMA Health Forum · 2022-06-17Spatiotemporal Mapping of Online Interest in Cannabis and Popular Psychedelics before and during the COVID-19 Pandemic in Poland.International journal of environmental research and public health · 2022-05-29Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant DepressionClinicalTrials.gov · 2022-05-20184. Hallucinogens on TikTokJournal of Adolescent Health · 2022-03-10A Randomized Controlled Trial of the Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Professional Leaders in ReligionClinicalTrials.gov · 2022-02-14Pennsylvania bill seeks clinical research on psychedelicsMental Health Weekly · 2022-01-14